GSK-VRX-RET-E22-303

Study Sponsor: GSK

Study Title

A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of study VRX-RET-E22-301)

Medicine or Vaccine (generic name)

retigabine

Sponsor Identification Number

VRX-RET-E22-303

Trial Registry Identification Number(#'s)

NCT00310375

Medical Condition

Epilepsy

Phase

Phase 3

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-303

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00310375

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

An annotated case report form is not available for this study. A blank case report form will be provided. This is a follow-up study to VRX-RET-E22-301.

Date Added to this Site

May 2020